Korro Bio, Inc.
KRROHealthcare|Biotechnology|US
$14.75
+0.02 (+0.14%)
DCF Value
$9.43
Tangible Book / Share
$4.95
Cash / Share
$5.88
Clinical Trials (2)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07773246 Phase 1/2 Study of KRRO-121 in Healthy Volunteers and Patients With UCD | Urea Cycle Disorders, Inborn, Urea Cycle Disorders | P1P2 | Recruiting | 30 | RCT, Double-blind | KRRO-121, Placebo |
| NCT06677307 A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110 | Alpha-1 Anti-trypsin Deficiency, AATD | P1P2 | Terminated | 42 | RCT, Double-blind | KRRO-110 |